The observation that ATR activity increases in response to CHK inhibition (Figure 5E, Supplementary Figure S7A) explains why many cancer cells can tolerate CHK1 monotherapy, possibly reflecting the ability of ATR to regulate origin firing, homologous-recombination repair, and/or nucleotide availability (77,88,89). Here, CHEK1 is linked to cancer.